Blog

Karen Knudsen: Identifying the science that can truly change the trajectory of cancer care

Photo of Karen Knudsen and Wafik S. El-Deiry

Jan 18, 2025, 14:46

Karen Knudsen: Identifying the science that can truly change the trajectory of cancer care

Karen Knudsen, Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS), shared a post by Wafik S. El-Deiry, Associate Dean for Oncologic Sciences at the Warren Alpert Medical School ,on LinkedIn:

“Love this post,Wafik S. El-Deiry! What might be hard to appreciate from the outside is how much time Cancer Center directors dedicate to supporting one another…… ideating, challenging dogma, sharing best practices through service on National Cancer Institute (NCI) Cancer Center external advisory boards (as just one example), and identifying the science that can truly change the trajectory of cancer care.

The 34% decline in cancer mortality since 1991 is no accident, and proof positive of importance of the National Cancer Institute (NCI) system. You have always been a luminary, Wafik, and the world is better for it. THANK YOU for what you do!”

Quoting Wafik S. El-Deiry‘s post:

“Early clinic today before heading to NYC on NCI service work for next couple of days.”

Karen Knudsen: Identifying the science that can truly change the trajectory of cancer care

Karen E. Knudsen is the Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health. She also served as president for the Association of American Cancer Institutes (AACI) and on the board of directors of the American Association for Cancer Research (AACR).

She serves on the board of advisors for the National Cancer Institute, on 12 external advisory boards for NCI-designated cancer centers and on Exai Bio. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals. He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.